ArticleEClinicalMedicine2023
First randomised controlled trial comparing the sirolimus-eluting bioadaptor with the zotarolimus-eluting drug-eluting stent in patients with
Article in EClinicalMedicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 28 citations in OpenAlex.
- A Comprehensive Meta-Analysis of Bioadaptor Versus Drug-Eluting Stents in Randomised Trials With Exploratory Single-Arm Landmark Analyses.European journal of clinical investigation · 2026Pooled it
- Site-Specific Antithrombotic Therapy: 24-Month Outcomes of the Randomized DESyne BDS Plus Trial Using a Novel Triple-Drug Eluting Coronary Implant With Two Anticoagulants and Sirolimus.Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions · 2025Trial
- Feasibility and short-term outcomes of bioadaptor in bifurcation intervention using culotte technique: intravascular ultrasound analysis from a single-center experience.Journal of cardiovascular imaging · 2026Article
- From Caging to Uncaging With Bioadaptors: A Novel Paradigm in Coronary Revascularization.Journal of the American Heart Association · 2026Review
- CVIT expert consensus document on primary percutaneous coronary intervention (PCI) for acute coronary syndromes (ACS) in 2026.Cardiovascular intervention and therapeutics · 2026Article
- Advances in Technology and Technique in Percutaneous Coronary Intervention: A Clinical Review.Internal medicine (Tokyo, Japan) · 2026Review
- Revisiting Bioresorbable Scaffolds in Light of the SCAAR Study.Journal of the Society for Cardiovascular Angiography & Interventions · 2025Article
- Coronary Bifurcation PCI-Part II: Advanced Considerations.Journal of cardiovascular development and disease · 2025Review
- DynamX Bioadaptor as an Emerging and Promising Innovation in Interventional Cardiology.Life (Basel, Switzerland) · 2025Review
- Long-Term Outcome of Percutaneous Coronary Intervention Using Absorb Bioresorbable Scaffold: A SCAAR Study.Journal of the Society for Cardiovascular Angiography & Interventions · 2025Article
- Advances in Clinical Cardiology 2024: A Summary of Key Clinical Trials.Advances in therapy · 2025Review
- Expanding the Role of Drug-Coated Balloons in Contemporary Percutaneous Coronary Intervention: Start of the Next Revolution or Just One More Weapon in a Growing Arsenal?Journal of the American Heart Association · 2025Article
- Physiological Scaffold Remodeling in the Coronary Artery After 30 Months of Bioadaptor Implantation.JACC. Case reports · 2025Article
- Clinical Updates in Coronary Artery Disease: A Comprehensive Review.Journal of clinical medicine · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors at 15 institutions in 5 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The DynamX™ bioadaptor is the first coronary implant technology with a unique mechanism of unlocking the bioadaptor frame after polymer resorption over 6 months, uncaging the vessel while maintaining a dynamic support to the vessel. It aims to achieve the acute performance of drug-eluting stents (DES) with the advantages of restoration of vessel function. Methods: This international, single blinded, randomised controlled (1:1) trial compared a sirolimus-eluting bioadaptor with a contemporary zotarolimus-eluting stent (DES) in 34 hospitals in Europe, Japan and New Zealand. Patients with Findings: 445 patients were randomised between January 2021 and February 2022. Device, lesion and procedural success rates, and acute gain were similar amongst the groups. The primary endpoint, 12-month target lesion failure, was 1.8% [95% CI: 0.5; 4.6] (n = 4) versus 2.8% [95% CI: 1.0; 6.0] (n = 6), p Interpretation: This is the first randomised controlled trial comparing the novel bioadaptor technology against a contemporary DES. The bioadaptor demonstrated similar acute performance and 12-month clinical outcomes, and superior imaging endpoints including restoration of vessel function. Funding: The study was funded by Elixir Medical.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.